November 18, 2026
Health news, explained with evidence
LIVE
Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia

Experts Evaluate Role of MRD Testing in Guiding Multiple Myeloma Treatment Duration

❤️ Conditions & Care 2 min read 👁 7

Hematology specialists discussed how minimal residual disease testing might help tailor the length of multiple myeloma therapy while balancing patient risk and quality of life.

Experts Evaluate Role of MRD Testing in Guiding Multiple Myeloma Treatment Duration❤️Conditions & Care

Photo: medpagetoday.com

Key points

  • City of Hope hematologists discussed using minimal residual disease testing to evaluate the duration of multiple myeloma maintenance therapy.
  • Sustained negative testing over two to three years may provide confidence to adjust therapy in standard-risk patients.
  • An estimated 5% to 7% of patients never achieve negative residual disease status but still maintain good long-term outcomes.

Hematology experts from City of Hope recently evaluated the evolving role of minimal residual disease testing in determining treatment duration for individuals with multiple myeloma. In a expert panel led by Dr. Joseph Mikhael, along with Dr. Amrita Krishnan and Dr. Tulio Rodriguez, clinicians discussed whether achieving minimal residual disease negativity—a standard indicating that highly sensitive tests detect no remaining cancer cells—can help determine when maintenance therapy might be safely adjusted or stopped.

While undetectable residual disease correlates with longer progression-free and overall survival, panel members stressed that treatment decisions cannot rely on testing results alone. Genomic risk profiles and clinical features such as extramedullary disease remain critical factors. For standard-risk patients, experts often look for sustained negative test results over two to three years before considering changes to therapy. Ongoing research, including the DRAMMATIC study, is assessing whether patients with negative testing at two years can discontinue maintenance, building on prior data from trials like FORTE that monitored sustained response over longer periods.

The specialists highlighted several practical limitations, noting that clear clinical guidelines are still lacking for patients who remain persistently positive on testing. Furthermore, roughly 5% to 7% of individuals with lower-risk disease never achieve undetectable residual status yet experience favorable long-term survival. Managing ongoing side effects such as fatigue and continuous gastrointestinal symptoms remains an important consideration in therapy decisions. What to know: Patients should consult their healthcare team before making any changes to their cancer treatment regimen.

Source medpagetoday.com — medpagetoday.com/meetingcoverage/ashroundtablemm/123900 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.